EMITF (Elbit Imaging) ROCE % : 23.45% (As of Jun. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Elbit Imaging ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Elbit Imaging's annualized ROCE % for the quarter that ended in Jun. 2024 was 23.45%.

Elbit Imaging ROCE % Historical Data

The historical data trend for Elbit Imaging's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elbit Imaging ROCE % Chart

Elbit Imaging Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-87.81

-6.37

-4.17

-4.94

-15.27

Elbit Imaging Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-12.17	2.12	-30.66	-0.48	23.45

Elbit Imaging ROCE % Calculation

Elbit Imaging's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.704	/	( ( (17.91 - 0.205)	+	(17.847 - 0.139) )	/ 2 )
	=	-2.704	/	( (17.705	+	17.708)	/ 2 )
	=	-2.704	/	17.7065
	=	-15.27 %

Elbit Imaging's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	4.414	/	( ( (17.847 - 0.139)	+	(20.018 - 0.087) )	/ 2 )
	=	4.414	/	( ( 17.708	+	19.931 )	/ 2 )
	=	4.414	/	18.8195
	=	23.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Elbit Imaging (OTCPK:EMITF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Elbit Imaging ROCE % Related Terms

Thank you for viewing the detailed overview of Elbit Imaging's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Elbit Imaging Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elbit Imaging Ltd (OTCPK:EMITF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EMITF-M:Israel

Address

3 Shimshon Street, Olympia A Tower, Petach Tikva, ISR, 4900102

Website

http://www.elbitimaging.com

Elbit Imaging Ltd is an Israel based company. The business activity of the group is operated through two segments including Medical industries and devices, and Plots in India. Geographically the business presence is in the region of America, Europe, and ROW. The company derives maximum revenue from the Medical industries and devices segment which operates in the field of life science that includes development, production, and marketing of treatment-oriented medical systems, and for certain cancer diseases in the America region.